Remove 2022 Remove Drug Development Remove Generic Medicine
article thumbnail

STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts

STAT

The state’s biotech scene   exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. But the   drumbeat of layoffs in 2022   has only grown louder this year.

Vaccines 313
article thumbnail

Small molecule API market to value $284.7 billion by 2032

European Pharmaceutical Review

billion in 2022. The small molecule API market is influenced by several factors, including heightened R&D within the pharmaceutical sector, a growing prevalence of chronic illnesses and rising demand for generic medicines. This is a rise from $162.8 A compound annual growth rate (CAGR) growth of 5.9

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Waters, as a strategic partner to the pharma industry, can help India become a world leader in biosimilars

Express Pharma

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?

article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. However, that percentage of multiple first generics is not very high—approximately 10.6% from 2001 to 2022.”